Acute leukemia is a heterogeneous group of disease reflecting stem cell of origin, capacity of maturation and commitment to a specific lineage. Leukemic cells may show early or minimal differentiation and some diagnostic entities can easily be confused with others because of their atypical immunophenotype.
Entities associated with a poor prognosis can be misdiagnosed as acute myeloid leukemia with minimal differentiation (AML-M0) if proper immunophenotyping panels are not routinely performed. In this webinar, Rafik Terra will explain how the use of the EuroFlow™ standardized approach has the potential to improve the diagnostic accuracy of rare entities like BPDCN and ETP-ALL.
